Duyuru • Aug 05
Wuxi Apptec Co., Ltd. Raises Full Year Guidance for the Fiscal Year 2026 WuXi AppTec Co., Ltd. raised full year guidance for the fiscal year 2026. For the period, the company's total revenue target raised to RMB 58.5 billion - RMB 60.5 billion (previously RMB 51.3 billion - RMB 53.0 billion), with Continuing Operations revenue growing 35-39% YoY (previously 18-22%). Duyuru • Jun 30
WuXi AppTec Co., Ltd. to Report First Half, 2026 Results on Aug 04, 2026 WuXi AppTec Co., Ltd. announced that they will report first half, 2026 results on Aug 04, 2026 Duyuru • Mar 30
WuXi AppTec Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 WuXi AppTec Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Duyuru • Mar 26
Wuxi Apptec Co., Ltd. Proposes Cash Dividend for the Year 2026 WuXi AppTec Co., Ltd. proposed cash dividend distribution plan totaling a record RMB 5.7 billion in 2026. Duyuru • Mar 24
WuXi AppTec Co., Ltd., Annual General Meeting, Apr 28, 2026 WuXi AppTec Co., Ltd., Annual General Meeting, Apr 28, 2026, at 14:00 China Standard Time. Location: sheraton shanghai waigaoqiao hotel, 28 jilong road, pilot free trade zone, shanghai., China Duyuru • Jan 12
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2025 WuXi AppTec Co., Ltd. provided earnings guidance for the full year 2025. For the year, total revenue is expected to be approximately RMB 45.46 billion, representing a year-over-year increase of approximately 15.8%, with revenue from Continuing Operations growing by approximately 21.4% year-over-year. Net profit after deducting non-recurring items is expected to be approximately RMB 13.24 billion, representing a year-over-year increase of approximately 32.6%. Net profit attributable to the owners of the Company is expected to be approximately RMB 19.15 billion. This represents a year-over-year increase of approximately 102.6%, including the investment income from sale of a partial interest in an associate and from divestiture of certain business. Basic earnings per share for the full year of 2025 is expected to be approximately RMB 6.70, representing a year-over-year increase of approximately 104.3%. Duyuru • Dec 26
WuXi AppTec Co., Ltd. to Report Fiscal Year 2025 Results on Mar 24, 2026 WuXi AppTec Co., Ltd. announced that they will report fiscal year 2025 results on Mar 24, 2026 Duyuru • Oct 27
WuXi AppTec Co., Ltd. Raises Earnings Guidance for They Full Year 2025 WuXi AppTec Co., Ltd. raised earnings guidance for they full year 2025 . For the year, company expected full-year total revenue of RMB 43.5 to RMB 44.0 billion, up from the prior RMB 42.5 Billion to RMB 43.5 billion. Duyuru • Sep 30
WuXi AppTec Co., Ltd. to Report Q3, 2025 Results on Oct 27, 2025 WuXi AppTec Co., Ltd. announced that they will report Q3, 2025 results on Oct 27, 2025 Duyuru • Sep 22
WuXi AppTec Co., Ltd. Implements First Interim Dividend Plan WuXi AppTec Co., Ltd. implemented its first interim dividend plan, distributing a total of RMB 1.03 billion in cash dividends. Duyuru • Aug 07
WuXi AppTec Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 7.695126 billion. WuXi AppTec Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 7.695126 billion.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 73,800,000
Price\Range: HKD 104.27
Transaction Features: Subsequent Direct Listing Duyuru • Jul 31
WuXi AppTec Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 7.695126 billion. WuXi AppTec Co., Ltd. has filed a Follow-on Equity Offering in the amount of HKD 7.695126 billion.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 73,800,000
Price\Range: HKD 104.27
Transaction Features: Subsequent Direct Listing Duyuru • Jul 10
Wuxi Apptec Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2025 to June 30, 2025 WuXi AppTec Co., Ltd. provided earnings guidance for the period from January 1, 2025 to June 30, 2025. For the year, The revenue of the Company was expected to be approximately RMB 20,799.28 million for the Current Period, representing a year-over-year increase of approximately 20.64%, revenue from continuing operations representing a year-over-year increase of approximately 24.24%. The net profit attributable to the owners of the Company after deducting non-recurring gain or loss items was expected to be approximately RMB 5,582.13 million for the Current Period, representing a year-over-year increase of approximately 26.47%. The net profit attributable to the owners of the Company was expected to be approximately RMB 8,560.88 million for the Current Period, representing a year-over-year increase of approximately 101.92%; the total profit of the Company was expected to be approximately RMB 9,907.42 million for the Current Period, representing a year-over-year increase of approximately 96.20%; and the basic earnings per share was expected to be approximately RMB 3.01 per share for the Current Period, representing a year-over-year increase of approximately 106.16%. Duyuru • Jun 30
WuXi AppTec Co., Ltd. to Report First Half, 2025 Results on Jul 29, 2025 WuXi AppTec Co., Ltd. announced that they will report first half, 2025 results on Jul 29, 2025 Duyuru • Jun 24
WuXi AppTec Co., Ltd.(SHSE:603259) dropped from Shanghai Stock Exchange 180 Value Index WuXi AppTec Co., Ltd. has been removed from Shanghai Stock Exchange 180 Value Index . Duyuru • Apr 29
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Year 2025 WuXi AppTec Co., Ltd. provided earnings guidance for the year 2025. "The Company currently maintains its full-year guidance set at the beginning of the year 2025. The company expects revenue from Continuing Operations to grow 10%-15% in 2025. Duyuru • Mar 28
WuXi AppTec Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 WuXi AppTec Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Duyuru • Mar 26
WuXi AppTec Co., Ltd., Annual General Meeting, Apr 29, 2025 WuXi AppTec Co., Ltd., Annual General Meeting, Apr 29, 2025, at 14:00 China Standard Time. Location: sheraton shanghai waigaoqiao hotel, 28 jilong road, pilot free trade zone, shanghai China Duyuru • Dec 27
WuXi AppTec Co., Ltd. to Report Fiscal Year 2024 Results on Mar 18, 2025 WuXi AppTec Co., Ltd. announced that they will report fiscal year 2024 results on Mar 18, 2025 Duyuru • Oct 05
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Two affiliated Chinese drug manufacturers targeted by forthcoming US national security legislation are working on sales of some of their operations, according to people familiar with the matter. WuXi AppTec Co., Ltd. (SHSE:603259) and WuXi Biologics (Cayman) Inc. (SEHK:2269) are among five China-based companies targeted by the Biosecure Act, which would ban drugmakers with US government contracts from using the Chinese groups’ services after 2032. The bipartisan bill overwhelmingly passed the House of Representatives last month and is making its way through the Senate. WuXi AppTec has put its cell and gene therapy manufacturing arm WuXi Advanced Therapies, Inc., which operates four laboratories and manufacturing facilities in Philadelphia, up for sale, according to three people familiar with the matter. Discussions have been ongoing for months and rival contract manufacturers have been approached about buying all or some of the assets. Separately, three people familiar with the situation said WuXi Biologics was working with advisers to test interest in some of its European production facilities, which management fears it may no longer need. New business in Europe has dried up in recent months, as biopharma companies with or seeking US federal contracts have become reluctant to use WuXi in light of the legislation. Revenues from European customers fell 27% in the first six months of 2024 compared to a year earlier, to RMB 1.8 billion ($260 million). WuXi Biologics told the FT it “continues to experience good business momentum. We are consistently securing new projects across all regions including the US, EU, China and the rest of Asia”. The Biosecure Act has made the pharmaceutical industry the latest sector subject to growing trade and national security tensions between the US and China after technology companies such as TikTok were targeted. Both WuXi entities, which are related but operate independently, are key cogs in the US and global pharmaceutical supply chain, playing a role in the production of AbbVie’s $3.5 billion a year cancer drug Imbruvica and Pfizer’s anti-Covid pill Paxlovid, among dozens of other medicines, according to GlobalData. More than 20 drugmakers, including AbbVie, have flagged their reliance on WuXi companies in regulatory filings this year, according to AlphaSense. Chief among WuXi Biologics’ assets being reviewed for sale are two German manufacturing facilities it bought from Bayer and spent extensively on expanding last year. WuXi Biologics also has large production facilities in Ireland. WuXi AppTec told the Financial Times it was “assessing options” for continuing its Advanced Therapies unit’s operations “in line with our priorities: our employees and the patients who need essential, time-critical and life-saving treatments”. WuXi Biologics said it “regularly conducts business reviews, with a focus on delivering a consistently high return on investment across all assets for our investors. We do not comment on market speculations”. With the Biosecure Act declaring WuXi “a biotechnology company of concern”, WuXi AppTec shares are down 14%, while those of WuXi Biologics have fallen nearly 30% this year. Cumulatively, both companies are valued at about $36 billion. People briefed on the sale processes said it was possible that the assets may not be sold. They added that WuXi AppTec and WuXi Biologics were seriously considering their options as they may no longer need as much production capacity as previously thought. WuXi Biologics may opt to keep their European facilities if existing clients decide to stick with them, as the Biosecure Act will take time to have an effect, a person said. Duyuru • Sep 30
WuXi AppTec Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024 WuXi AppTec Co., Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024 Duyuru • Sep 11
WuXi AppTec Co., Ltd. (SHSE:603259) announces an Equity Buyback for CNY 1,000 million worth of its shares. WuXi AppTec Co., Ltd. (SHSE:603259) announces a share repurchase program. Under the program, the company will repurchase up to CNY 1,000 million worth of its A shares. The shares will be repurchased at a price not more than CNY 61.02 per share. The purpose of the program is to safeguard the company's value and the interests of shareholders; and to enhance investor’s confidence. After the repurchase is completed, all the shares repurchased will be canceled and the registered capital will be reduced. The company will use its own funds to repurchase its shares. The program will be valid for a period of 3 months. Duyuru • Jun 28
WuXi AppTec Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024 WuXi AppTec Co., Ltd. announced that they will report first half, 2024 results on Jul 30, 2024 Duyuru • Jun 13
WuXi AppTec Co., Ltd. Approves Cash Dividend Payment for the Financial Year Ended 31 December 2023, Payable on July 5, 2024 WuXi AppTec Co., Ltd. approved cash dividend payment of RMB 9.8974 per 10 share for the financial year ended 31 December 2023 at its shareholders' meeting held on 12 June 2024. Ex-dividend date: 17 June 2024. Record date: 25 June 2024. Expected date of 2023 Profit Distribution is July 5, 2024. Duyuru • May 12
WuXi AppTec Co., Ltd., Annual General Meeting, Jun 12, 2024 WuXi AppTec Co., Ltd., Annual General Meeting, Jun 12, 2024, at 14:00 China Standard Time. Location: sheraton shanghai waigaoqiao hotel, 28 jilong road, pilot free trade zone, shanghai China Duyuru • May 10
Wuxi Apptec Co., Ltd. Proposes Final Cash Dividend Payment for the Financial Year Ended 31 December 2023 WuXi AppTec Co., Ltd. proposed final cash dividend payment of RMB 9.8336 per 10 share for the financial year ended 31 December 2023 at its shareholders' meeting to be held on 12 June 2024.Ex-dividend date: 17 June 2024. Record date: 25 June 2024. Duyuru • Apr 30
WuXi AppTec Co., Ltd. Provides Earnings Guidance for the Full Year 2024 WuXi AppTec Co., Ltd. provided earnings guidance for full year of 2024. For the full year, the Company expects to deliver revenue of RMB 38.3 billion - RMB 40.5 billion. Duyuru • Mar 29
WuXi AppTec Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 WuXi AppTec Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Duyuru • Mar 20
WuXi AppTec Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended December 31, 2023 WuXi AppTec Co., Ltd. proposed final ordinary dividend of RMB 9.8336 per 10 share for the year ended December 31, 2023. Duyuru • Dec 29
WuXi AppTec Co., Ltd. to Report Fiscal Year 2023 Results on Mar 19, 2024 WuXi AppTec Co., Ltd. announced that they will report fiscal year 2023 results on Mar 19, 2024 Duyuru • Jun 28
WuXi AppTec Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023 WuXi AppTec Co., Ltd. announced that they will report first half, 2023 results on Aug 01, 2023 Duyuru • Jun 07
WuXi AppTec Co., Ltd. Announces Executive Changes The board of directors of WuXi AppTec Co., Ltd. announced that Mr. Chi YAO has resigned as (i) a joint company secretary of the Company ("Joint Company Secretary"); The Board further announces that Mr. Yuanzhou ZHANG has been appointed as Joint Company Secretary, Authorised Representative and Process Agent in replacement of Mr. Yao with effect from June 6, 2023. Mr. Zhang, aged 34, holds a Master's degree and is a Chinese national. He currently serves as the Senior Director of the Mergers and Acquisitions Department of the Company. Mr. Zhang served as a Management Trainee and a Relationship Manager of the Global Banking Department in HSBC Bank (China) Company Limited from June 2013 to April 2016. From May 2016 to September 2018, he served as a Vice President of the Investment Banking Department in CSC Financial Co., Ltd. Since October 2018, Mr. Zhang has served various positions in the Company, including Investment Director of the Corporate Development and Investment Department, as well as Senior Director of the Mergers and Acquisitions Department. His primary responsibilities entail conducting industry mergers and acquisitions, equity investments and strategic collaborations which are aligned with core businesses of the Company. Mr. Zhang obtained a Bachelor's degree in Economics from the Central University of Finance and Economics. He also obtained a Master's degree in Finance from the Olin Business School at Washington University in St. Louis in the United States. Ms. CHEUNG Yuet Fan ("Ms. Cheung"), an existing joint company secretary of the Company, will continue with the role and act as the other Joint Company Secretary and Process Agent. Ms. Cheung is a director of Corporate Services of Tricor Services Limited, a global professional services provider specialising in integrated business, corporate and investor services. Ms. Cheung is a Chartered Secretary, a Chartered Governance Professional and a Fellow of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Cheung has over 25 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Cheung obtained a Bachelor of Arts degree in Accountancy from City Polytechnic of Hong Kong (now known as City University of Hong Kong) in November 1993. Duyuru • May 18
Wuxi AppTec Co., Ltd Announces Demise of Ning Zhao, Executive Director and Senior Vice President WuXi AppTec Co., Ltd. announced that Dr. Ning Zhao, the co-founder, one of the actual controllers, executive director and senior vice president of the Company, has passed away on May 16, 2023. Dr. Zhao was an extraordinary scientist, leader and philanthropist with an unwavering commitment to improving human health. She obtained her bachelor's degree in chemistry from Peking University, doctoral degree in organic chemistry from Columbia University, and then began her remarkable career with top organizations, advancing through the ranks of research and management. As one of our co-founders, Dr. Zhao played an instrumental role in shaping our Company into what it is today. She built our integrated bioanalytical capabilities with global regulatory standards a cornerstone of our testing platform and CRDMO/CTDMO model today. She also spearheaded the Company's talent development strategies and HR transformations that have become award-winning industry best practices. Duyuru • Jan 31
Wuxi Apptec Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022 WuXi AppTec Co., Ltd. provided earnings guidance for the year ended December 31, 2022. The company is expecting to record an increase in the revenue and net profit attributable to shareholders of the Company for the year ended December 31, 2022 in comparison with the corresponding period in the year of 2021. Duyuru • Aug 07
WuXi AppTec Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 7.366183 billion. WuXi AppTec Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 7.366183 billion.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 68,205,400
Price\Range: HKD 108
Transaction Features: Subsequent Direct Listing Duyuru • Jul 06
WuXi AppTec Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020 WuXi AppTec Co., Ltd. announced that they will report first half, 2020 results on Aug 14, 2020 
